Business Context and Reporting Period
Radiopharm Theranostics Limited, a foreign private issuer based in Australia, filed Form 6-K for the month of September 2025. The filing, dated September 17, 2025, serves to report a corporate announcement made to the Australian Securities Exchange (ASX) titled "Corporate Governance Statement and Appendix 4G."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to disclose a corporate governance announcement and does not contain financial performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this document. The filing focuses solely on the publication of the Corporate Governance Statement and Appendix 4G.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It explicitly states that the report and its exhibits shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly set forth.
Key Facts for Investor Verification
- The filing is a Form 6-K reporting a non-financial corporate governance announcement.
- The primary exhibit (99.1) contains the "Corporate Governance Statement and Appendix 4G."
- No financial results or operational metrics are included in this specific document.
- Investors should review the attached Exhibit 99.1 for details on the company's governance framework.